Investigating and Targeting Hepatic Steatosis Induced by Tamoxifen

Abstract

Breast cancer (BC) is the most frequent cancer in women all over the world. It is the second leading cause of cancer related death cases among women. Tamoxifen is widely used for the treatment of hormone-responsive BC because of two significant advantage: it is inexpensive and is well tolerated. Tamoxifen therapy has been linked to the development of fatty liver. Recently, multiple reports have also associated TAM with cognitive impairment in breast cancer patients. Luteolin, a natural flavonoid, has been traditionally used for treating various inflammatory disorders including liver diseases, cognitive impairments and cancer. This study aimed to evaluate the potential protective effect of luteolin in TAM-induced cognitive deficits and liver steatosis. Animals Eight-week-old male albino rats weighing about (150–200 g) were obtained from an animal breeding facility (National Research Center, Giza, Egypt). The animals were housed in cages at a constant temperature of 25°C under 12 h day/night cycle. They were given free access to food pellets and water ad libitum and left to acclimatize the laboratory environment for 1 week before the experiment. All the experimental procedures were approved by the Research Ethics Committee, Faculty of Pharmacy, Ain Shams University, Egypt under the memorandum no 82.